Key result
Concurrent therapies including probucol, carvedilol, dexrazoxane, and antioxidants are being studied to attenuate doxorubicin-induced cardiomyopathy while maintaining antitumor efficacy.
Answers are grounded in this paper and cite their sources.
This review highlights concurrent therapies such as carvedilol and dexrazoxane that may attenuate doxorubicin-induced cardiomyopathy, emphasizing the role of nurses in patient education and assessment.
Doxorubicin is a chemotherapeutic agent successfully used in the treatment of a wide range of cancers. However, with cumulative doses, doxorubicin also is known to have cardiotoxic effects, including cardiomyopathy and heart failure. Research is targeted at maximizing the antitumor effects of doxorubicin while attenuating the potential cardiotoxicity. Concurrent therapies under study are combinations of doxorubicin with drugs such as probucol, carvedilol (Coreg, GlaxoSmithKline, Research Triangle Park, NC), dexrazoxane (Zinecard, Pfizer, New York, NY), and antioxidant nutrients. As patient advocates, nurses must be aware of current research, treatment options, and evidence-based patient resources and be diligent in assessing and educating patients before, during, and after treatment with doxorubicin.
No takes yet. Share an insight, caveat, or question.
Simpson et al. (2004) conducted a review in Doxorubicin-induced cardiomyopathy. Concurrent therapies (probucol, carvedilol, dexrazoxane, antioxidant nutrients) was evaluated. Concurrent therapies including probucol, carvedilol, dexrazoxane, and antioxidants are being studied to attenuate doxorubicin-induced cardiomyopathy while maintaining antitumor efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: